Eterna Therapeutics jumps on cancer therapy options agreement
17/10/2022 16:14
** Shares of Eterna Therapeutics Inc ERNA.O rise ~12% to
$4.6 in morning trade
** Stock among top pct gainers on the Nasdaq Biotechnology
Index .NBI
** Eterna, previously known as Brooklyn ImmunoTherapeutics,
enters into an option agreement with private firm Exacis
Biotherapeutics urn:newsml:reuters.com:*:nGNX1QsRnH
** Co says agreement grants ERNA right to negotiate an
exclusive license to develop up to four iPS cell-derived natural
killer cell and/or T cell therapies for cancer treatment
** iPS cell-derived therapies are made from reprogrammed
skin or blood cells and are used in the treatment of various
diseases including diabetes and several types of cancer
** Both companies have until Dec. 31 to negotiate and
execute a license agreement, says ERNA
** As of last close, ERNA down ~95% vs a ~18% decline in
.NBI YTD
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))